臨床外科69巻6号

2014年06月発行

特集 癌の補助療法アップデート

食道胃接合部癌―世界のエビデンスとわが国の今後

著者： 山下裕玄¹ 瀬戸泰之¹

所属機関： ¹東京大学医学部附属病院胃食道外科

ページ範囲：P.662 - P.667

文献概要

【ポイント】

◆近年増加傾向にある食道胃接合部癌に限定した臨床試験はなく，食道癌・胃癌の臨床を外挿しているに過ぎない．

◆海外では術後局所再発率が高く，術前放射線化学療法により改善が得られているが，わが国では局所再発は少ない．

◆リンパ節転移が強い予後規定因子であるのは世界共通であり，術前補助化学療法の対象として最も適している．

参考文献

1）日本食道学会（編）：食道癌取扱い規約．金原出版，2008

2）日本胃癌学会（編）：胃癌取扱い規約．金原出版，2010

3）Suh YS, Han DS, Kong SH, et al：Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer?：a comparative analysis according to the seventh AJCC TNM classification. Ann Surg 255：908-915, 2012

4）Hasegawa S, Yoshikawa T, Aoyama T, et al：Esophagus or stomach? The seventh TNM classification for Siewert type Ⅱ/Ⅲ junctional adenocarcinoma. Ann Surg Oncol 20：773-779, 2013

5）Kawaguchi T, Komatsu S, Ichikawa D, et al：Comparison of prognostic compatibility between seventh AJCC/TNM of the esophagus and 14th JCGC staging systems in Siewert type Ⅱ adenocarcinoma. Anticancer Res 33：3461-3465, 2013

6）Yamashita H, Katai H：Should adenocarcinoma of the esophagogastric junction be classified as esophageal cancer? Limited to Siewert type Ⅱ, Yes. Ann Surg, in press

7）Kazui T, Osada H, Fujita H, Japanese Association for Thoracic Surgery Committee for Scientific A：Thoracic and cardiovascular surgery in Japan during 2004. Jpn J Thorac Cardiovasc Surg 54：363-385, 2006

8）Kuwano H, Amano J, Yokomise H：Thoracic and cardiovascular surgery in Japan during 2010：annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg 60：680-708, 2012

9）Kusano C, Gotoda T, Khor CJ, et al：Changing trends in the proportion of adenocarcinoma of the esophagogastric junction in a large tertiary referral center in Japan. J Gastroenterol Hepatol 23：1662-1665, 2008

10）Yamashita H, Katai H, Morita S, et al：Optimal extent of lymph node dissection for Siewert type Ⅱ esophagogastric junction carcinoma. Ann Surg 254：274-280, 2011

11）Fujitani K, Miyashiro I, Mikata S, et al：Pattern of abdominal nodal spread and optimal abdominal lymphadenectomy for advanced Siewert type II adenocarcinoma of the cardia：results of a multicenter study. Gastric Cancer 16：301-308, 2013

12）Yabusaki H, Nashimoto A, Matsuki A, et al：Comparison of the surgical treatment strategies for Siewert type II squamous cell carcinoma in the same area as esophagogastric junction carcinoma：data from a single Japanese high-volume cancer center. Surg Today, 2013

13）Katai H, Maruyama K, Sasako M, et al：Mode of recurrence after gastric cancer surgery. Dig Surg 11：99-103, 1994

14）Stahl M, Walz MK, Stuschke M, et al：Phase Ⅲ comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27：851-856, 2009

15）van Hagen P, Hulshof MC, van Lanschot JJ, et al：Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366：2074-2084, 2012

16）Wayman J, Bennett MK, Raimes SA, et al：The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction. Br J Cancer 86：1223-1229, 2002

17）Reeh M, Mina S, Bockhorn M, et al：Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. Br J Surg 99：1406-1414, 2012

18）Sudo K, Taketa T, Correa AM, et al：Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 31：4306-4310, 2013

19）Macdonald JS, Smalley SR, Benedetti J, et al：Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345：725-730, 2001

20）Cunningham D, Allum WH, Stenning SP, et al：Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355：11-20, 2006

21）Cunningham D, Starling N, Rao S, et al：Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358：36-46, 2008

22）Schuhmacher C, Gretschel S, Lordick F, et al：Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia：European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 28：5210-5218, 2010

23）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer （ToGA）：a phase 3, open-label, randomised controlled trial. Lancet 376：687-697, 2010

24）Waddell T, Chau I, Cunningham D, et al：Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer （REAL3）：a randomised, open-label phase 3 trial. Lancet Oncol 14：481-489, 2013

25）Lordick F, Kang YK, Chung HC, et al：Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer （EXPAND）：a randomised, open-label phase 3 trial. Lancet Oncol 14：490-499, 2013

26）Matsuda T, Takeuchi H, Tsuwano S, et al：Optimal surgical management for esophagogastric junction carcinoma. Gen Thorac Cardiovasc Surg, 2014